Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PSTVZ - Plus Therapeutics Inc Warrant 2019-28.05.20 On Plus Therapeuts Rg Series S

Previous close
0.007
0   0%

Share volume: 0
Last Updated: Tue 26 May 2020 06:00:00 AM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
$0.01
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
59%
Profitability 75%
Dept financing 25%
Liquidity 0%
Performance 65%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.01
P/E Ratio 
N/A
DAY RANGE
$0.01 - $0.01
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
4.111 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Marc H. Hedrick
Region: US
Website: http://www.plustherapeutics.com
Employees: 0
IPO year: -
Issue type:
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Recent news